PETHEMA

Name

PETHEMA

Legal name

FUNDACIÓN PETHEMA

Website

https://fundacionpethema.es

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Academic Clinical Research (Hematology)

NAICS

Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Clinical hematology research
• Academic cooperative trials
• Leukemia research groups
• Real-world clinical data
• Clinical research foundation

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Distribution channels1 record

Marketing channels3 records

Core offering

PETHEMA is a non-profit academic cooperative research group that conducts independent clinical research in hematology through disease-focused working groups (multiple myeloma, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myelodysplastic syndromes, primary immune thrombocytopenia). It delivers cooperative clinical trials, real-world data registries, clinical guidelines, peer-reviewed publications, and research grants, while operating REDCap and GEM-Sys clinical data management platforms.

Product overview

PETHEMA is a cooperative academic clinical research group affiliated with the Spanish Society of Hematology and Hemotherapy (SEHH). The organization operates a platform of specialized research working groups focused on different hematological diseases, including GEM (multiple myeloma), LMA (acute myeloid leukemia), LAL (acute lymphoblastic leukemia), LLC (chronic lymphocytic leukemia), IM, SMD (myelodysplastic syndromes), and PTI. The core infrastructure includes REDCap and GEM-Sys data management platforms, a clinical registry (NCT02607059), and the GRANT-HEMA scholarship program. PETHEMA integrates academic research from Spanish public hospitals with European and Latin American centers, providing clinical guidelines, organizing scientific events and workshops, and publishing research findings in hematology.

Differentiator

Problem solved

Functional benefit

Products and services

• GEM Working Group (Multiple Myeloma) Cooperative academic research working group dedicated to clinical research, treatment development, and protocols for multiple myeloma and plasma cell disorders, open to participating hematologists across the PETHEMA network.
• LMA Working Group (Acute Myeloid Leukemia) Cooperative research working group focused on clinical research, treatment development, and molecular diagnostics for acute myeloid leukemia patients across Spain, Portugal, and Latin America.
• LAL Working Group (Acute Lymphoblastic Leukemia) Cooperative research working group conducting clinical studies and developing treatment protocols for acute lymphoblastic leukemia patients within the PETHEMA network.
• LLC Working Group (Chronic Lymphocytic Leukemia) Cooperative research working group focused on clinical research and treatment development for chronic lymphocytic leukemia patients.
• SMD Working Group (Myelodysplastic Syndromes) Cooperative research working group focused on clinical research and treatment development for myelodysplastic syndromes within the PETHEMA network.
• PTI Working Group (Primary Immune Thrombocytopenia) Cooperative research working group focused on clinical research in primary immune thrombocytopenia.
• IM Working Group Internal Medicine research working group within the PETHEMA cooperative network.
• PETHEMA Clinical Registry (NCT02607059) Clinical registry collecting real-world data from adult acute myeloid leukemia patients for cooperative research purposes, operated across the PETHEMA network.
• GEM-Sys Research Data Management System Specialized research data management system for the GEM (multiple myeloma) working group, available at gemsys.fundacionpethema.com.
• REDCap Platform (Clinical Data Capture) Electronic data capture system operated by PETHEMA for clinical research data management across its studies, available via redcap.fundacionpethema.com and rc.fundacionpethema.com.
• GRANT-HEMA Research Scholarships Annual research scholarship program providing grants to support academic clinical research in hematology, awarded through open calls to researchers.
• PETHEMA Clinical Guidelines Clinical and drug guidelines developed by the PETHEMA cooperative group for the treatment of hematological diseases, made available to participating institutions and clinicians.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• Hospital La Fe (Valencia)coreStrategic or Co-development Partner · 24 April 2026Strategic alliance 'La Alianza que Salva Vidas' between PETHEMA Foundation and Hospital La Fe for cooperative research in acute myeloid leukemia. Represents one of the largest cooperative research structures in Europe, integrating over 300 centers and 1,000 researchers from Spain, Portugal, and Latin America. The collaboration facilitates early access to innovative treatments for patients.
• SEHH (Sociedad Española de Hematología y Hemoterapia)coreStrategic or Co-development PartnerPETHEMA is a cooperative academic research group affiliated with the Spanish Society of Hematology and Hemotherapy (SEHH), integrating clinical hematologists and researchers from Spanish public hospitals along with European and Latin American centers.
• Public Hospitals NetworkcoreStrategic or Co-development PartnerNetwork of public hospitals across Spain, Portugal, and Latin America participating in cooperative hematology research, with over 300 centers and 1,000+ researchers involved in clinical studies.

Scale indicators3 records

Expansion highlights5 records

Broad incumbents

• EORTC (European Organisation for Research and Treatment of Cancer): Pan-European clinical research organization conducting cancer trials across multiple tumor types. Broader incumbent to PETHEMA in scope, but both run academic multicenter clinical trials and serve as cooperative partners for biopharma sponsors across European public hospital networks.
• SWOG Cancer Research Network: Large US-based NCI-sponsored cooperative oncology trial group. Broader incumbent with materially similar cooperative academic trial model, though operating at national scale across North America rather than a single regional cluster.
• CIBMTR (Center for International Blood and Marrow Transplant Research): US-based collaborative research organization maintaining large hematology outcome registries and conducting observational and interventional studies. Comparable to PETHEMA in registry-driven real-world evidence generation in hematology, though operating at international scale.
• EBMT (European Society for Blood and Marrow Transplantation): European professional society running registry-based studies and clinical trials in stem cell transplantation and cellular therapy. Broader incumbent with overlapping scope in hematology, partnering with academic cooperative groups including PETHEMA-style networks.

Direct peers

• GMALL (German Multicenter Acute Lymphoblastic Leukemia Study Group): German cooperative research group focused on adult ALL. Comparable to PETHEMA's LAL working group, running multicenter academic trials and treatment protocols across public hospitals in Germany.
• ALWP (Acute Leukemia Working Party) of EBMT: Working party within EBMT focused on acute leukemia clinical studies and registry research. Directly comparable to PETHEMA's LMA working group in scope, running multicenter academic studies and real-world evidence analyses in AML and ALL.
• HOVON (Dutch-Belgian Hemato-Oncology Group): Dutch-Belgian cooperative group for hemato-oncology research. Direct peer to PETHEMA: both run academic multicenter trials in leukemia, lymphoma, and myeloma across public hospitals and partner with biopharma on cooperative studies.
• LYSA (Lymphoma Study Association): French-led European cooperative group dedicated to lymphoma clinical research. Direct peer to PETHEMA in the academic cooperative trial model, focused on hematological malignancies across European public hospitals.
• GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto): Italian national cooperative group for adult hematological diseases. Direct peer to PETHEMA: both are academic cooperative research networks running multicenter clinical trials in leukemia, lymphoma, and myeloma across public hospital systems in their respective countries.

Regional players

• Grupo de Estudos de Mieloma (Brazil): Brazilian academic cooperative focused on multiple myeloma research, sharing the 'GEM' branding convention with PETHEMA's myeloma working group. Regional peer serving Latin American public hospitals with overlapping multiple myeloma clinical trial activity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/fundacion-pethema

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PETHEMA